

Supplemental Table 1 – Summary of some ^{11}C tracer dosimetry studies

| Radiotracer | Effective Dose (mSv MBq $^{-1}$) | Top Organ & Dose (mSv MBq $^{-1}$) | Reference |
|---|---|--|---------------|
| [^{11}C]ABP688 | 3.7×10^{-3} (effective dose equivalent) | Liver 1.6×10^{-2} | (1) |
| [^{11}C]Acetate | 4.9×10^{-3} | Pancreas 1.7×10^{-2} | (2) |
| [^{11}C]DASB | 7.0×10^{-3} | Lung 3.2×10^{-2} | (3) |
| [^{11}C]Glucose | 4.3×10^{-3} | Brain 1.2×10^{-2} | (4) |
| [^{11}C]Methionine | 5.2×10^{-3} | Pancreas 2.3×10^{-2} | (5) |
| [^{11}C]Methoxyprogabidic acid | 4.8×10^{-3} | Small intestine 3.1×10^{-2} only “Critical organs“ reported | (6) |
| [^{11}C]Mirtazapine | 6.8×10^{-3} | Lungs 3.2×10^{-2} | (7) |
| [^{11}C]MP4B | 4.2×10^{-3} | Urinary Bladder Wall 1.9×10^{-2} | (8) |
| [^{11}C]NNC 112 | 5.7×10^{-3} | Gallbladder wall 3.2×10^{-2} | (9) |
| [^{11}C]NPA | 6.7×10^{-3} | Gallbladder wall 2.8×10^{-2} | Current study |
| [^{11}C]Raclopride | 6.3×10^{-3} | Gallbladder 3.2×10^{-2} | (10) |
| [^{11}C]Raclopride | 6.7×10^{-3} | Kidneys 4.1×10^{-2} | (11) |
| [^{11}C]WAY100635 | 14.1×10^{-3} | Urinary bladder wall 19×10^{-2} | (12) |

SUPPLEMENTAL REFERENCES

1. Treyer V, Streffer J, Ametamey SM, et al. Radiation dosimetry and biodistribution of ¹¹C-ABP688 measured in healthy volunteers. *European Journal of Nuclear Medicine and Molecular Imaging*. Apr 2008;35(4):766-770.
2. Seltzer MA, Jahan SA, Sparks R, et al. Radiation dose estimates in humans for C-11-acetate whole-body PET. *Journal of Nuclear Medicine*. Jul 2004;45(7):1233-1236.
3. Lu JQ, Ichise M, Liow JS, Ghose S, Vines D, Innis RB. Biodistribution and radiation dosimetry of the serotonin transporter ligand C-11-DASB determined from human whole-body PET. *Journal of Nuclear Medicine*. 2004;45(9):1555-1559.
4. Graham MM, Peterson LM, Muzi M, et al. 1-[Carbon-11]-glucose radiation dosimetry and distribution in human imaging studies. *Journal of Nuclear Medicine*. Oct 1998;39(10):1805-1810.
5. Deloar HM, Fujiwara T, Nakamura T, et al. Estimation of internal absorbed dose of L-[methyl-C-11]methionine using whole-body positron emission tomography. *European Journal of Nuclear Medicine*. Jun 1998;25(6):629-633.
6. Santens P, De Vos F, Thierens H, et al. Biodistribution and dosimetry of carbon-11-methoxyprogabidic acid, a possible ligand for GABA-receptors in the brain. *Journal of Nuclear Medicine*. Feb 1998;39(2):307-310.
7. Marthi K, Hansen SB, Jakobsen S, Bender D, Smith SB, Smith DF. Biodistribution and radiation dosimetry of [N-rnethy-C-11]mirtazapine, an antidepressant affecting adrenoceptors. *Applied Radiation and Isotopes*. Aug-Sep 2003;59(2-3):175-179.
8. Virta JR, Tolvanen T, Nagren K, Bruck A, Roivainen A, Rinne JO. 1-C-11-Methyl-4-piperidinyl-N-butyrate radiation dosimetry in humans by dynamic organ-specific evaluation. *Journal of Nuclear Medicine*. Mar 2008;49(3):347-353.
9. Cropley VL, Fujita M, Musachio JL, et al. Whole-body biodistribution and estimation of radiation-absorbed doses of the dopamine D-1 receptor radioligand C-11-NNC 112 in humans. *Journal of Nuclear Medicine*. Jan 2006;47(1):100-104.
10. Slifstein M, Hwang DR, Martinez D, et al. Biodistribution and radiation dosimetry of the dopamine D-2 ligand C-11-raclopride determined from human whole-body PET. *Journal of Nuclear Medicine*. Feb 2006;47(2):313-319.
11. Ribeiro MJ, Ricard M, Bourgeois S, et al. Biodistribution and radiation dosimetry of [C-11]raclopride in healthy volunteers. *European Journal of Nuclear Medicine and Molecular Imaging*. Aug 2005;32(8):952-958.
12. Parsey RV, Belanger MJ, Sullivan GM, et al. Biodistribution and radiation dosimetry of C-11-WAY100,635 in humans. *Journal of Nuclear Medicine*. Apr 2005;46(4):614-619.